Sentences with phrase «than growth stocks over»

Not exact matches

Sales were flat in North America, compared with a 38 percent growth in the Asia - Pacific region, but that was enough to knock 5 percent off the stock which has gained more than two - thirds in value over the past year.

The extra growth you get on your stock market portfolio, compounded over 30 years, will more than make up for what you lose on rental inflation.

These risks and uncertainties include: Gilead's ability to achieve its anticipated full year 2018 financial results; Gilead's ability to sustain growth in revenues for its antiviral and other programs; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for new products, including Vosevi, Yescarta, Epclusa, Harvoni, Genvoya, Odefsey, Descovy, Biktarvy and Vemlidy ®; austerity measures in European countries that may increase the amount of discount required on Gilead's products; an increase in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers; a larger than anticipated shift in payer mix to more highly discounted payer segments and geographic regions and decreases in treatment duration; availability of funding for state AIDS Drug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the SEC).

But anyone hoping for the kind of stock growth Shoppers enjoyed over the past decade — when its share price climbed from less than $ 18 to, at one point, over $ 55 — will be disappointed.

The r - squared value of 0.0006 in Figure 1 shows that EPS growth over the past five years explains less than one tenth of one percent of the difference in price between stocks in the S&P 500.

Strategic Growth is a risk - managed growth fund that is intended to accept exposure to U.S. stocks over the full market cycle, but with smaller periodic losses than a passive buy - and - hold appGrowth is a risk - managed growth fund that is intended to accept exposure to U.S. stocks over the full market cycle, but with smaller periodic losses than a passive buy - and - hold appgrowth fund that is intended to accept exposure to U.S. stocks over the full market cycle, but with smaller periodic losses than a passive buy - and - hold approach.

We would cease to be an emerging growth company if we have more than $ 1.0 billion in annual revenue, have more than $ 700 million in market value of our Class A common stock held by non-affiliates, or issue more than $ 1.0 billion of non-convertible debt over a three - year period.

Therefore, I think the stock is likely to grow at a faster pace than earnings growth over the next year.

Analysts are now forecasting more than 21 percent earnings growth for the median stock over the next year, a record level in the 30 years of data.

Issues defined as «growth stocks» have a number of common traits, but the most important is that their earnings are expected to grow at a faster pace than the broader market over a period of time.

While value stocks, by definition, will trade at a lower valuation than growth stocks, the valuation spread moves over time.

The respected market - research firm Ned Davis conducted a study over more than four decades in which they analyzed the total returns of dividend and growth stocks.

However, every academic I'm familiar with expects that, over the long term, stocks will continue to have higher returns than bonds, that small - cap stocks will continue to have higher returns than large - cap stocks and that value stocks will continue to have higher returns than growth stocks.

One, the prices of dividend stocks tend to be less volatile over time than non-dividend payers or «growth» stocks.

Such a portfolio would return about $ 19,000 a year, a little less than the single - life pension option but alternatively, her stocks would give her years worth of growth as well as the annual dividend income which should increase over the years.

Seeks to deliver long - term growth of capital over a full market cycle and dividend income greater than the S&P 500 ® Index, with the potential for less volatility than the U.S. stock market

While value stocks, by definition, will trade at a lower valuation than growth stocks, the valuation spread moves over time.

If your client is looking to grow her wealth over the long - term and is not concerned with generating immediate income, funds that focus on growth stocks and use a buy - and - hold strategy are best because they generally incur lower expenses and have a lower tax impact than other types of funds.

By adding growth stocks in combination with high ROIC stocks, the $ 1,000 grows to more than $ 15,000 over the same period.

Your decision to invest is a GROWTH decision because the performance of the stock market is always more positive than negative over a period of time.

Because sometimes this value premium, it's not there for a year or two, or even five years, sometimes growth stocks are better than small value over a five year period, six year period.

They identify the point where the lines of the two choices cross and conclude something like «Over 20 years you receive more $ $ from high dividend - growth stocks than from high - yield dividend stocks, so it is better to buy high dividend - growth stocks.»

«My holdings of company stock are higher than I'd like but the growth and dividend history over the past five years have been impressive with still a lot of room for continued growth,» says Shaun.

Editorially, Kiplinger's magazine has championed over the decades a number of personal finance strategies and investment products that later became popular «conventional wisdom»: the superiority of systematic investing (dollar cost averaging) over market timing; growth stocks that paid little or no dividends but invested in new technologies; mutual funds, especially no - load funds; stock index funds; term life insurance, rather than whole - life; and global investing.

Despite the trust's name, it has long focused more on value than growth stocks (think Shell and Lloyds), which hasn't been working — the trust has underperformed the FTSE All - Share over three and five years and the shares have traded at a nasty discount to net asset value.

But rather than avoid the US, or agonise over the timing of a potential buy, I think it presents the ideal opportunity to slowly but surely average into high quality US growth stocks which have already (and / or perhaps will still) suffer a temporary share price / valuation setback.

Rather than focusing on current yield, the ETF instead looks at stocks that have a past history of dividend growth over time.

He pointed out that the promised growth was far less than the stock market's likely return over the next 30 years.

4) The UK, France, and Switzerland all had poor stock performance over the past two decades, partially because their markets were overvalued in 2000 and partially because they have slower population growth than the United States.

The biggest investment by T. Rowe Price's 2035 fund (T. Rowe Price Growth Stock Fund) holds just over 100 companies that it hopes will generate better - than - average market returns.

Even though this investment has been a dud compared to the indices, it has paid me more than $ 2,300 in dividends over the years, and it remains a solid pillar of my dividend growth stock portfolio.

In order to make sure that I'm on the right path to reach my 8 % dividend growth goal, I decided to make a list of all the stocks that have increased their dividends for more than 25 straight years, but that also increased that dividend at a rate of at least 8 % per year over the last 10 years, 5 years, 3 years and 1 year!